Articles

4 Items

Journal Article - AgBioForum: The Journal of AgroBiotechnology Management & Economics

Political Actors on the Landscape

| 2007

"Efforts to introduce novel agricultural crops or foods are welcomed and supported by some politically important groups in the developing world, ignored by others, and at times opposed by a significant few. When considering the political actors on the landscape most likely to take active positions either for or against novel foods, there is little or no evidence of political resistance to any of the biofortified foods developed thus far using conventional crop-breeding techniques, yet resistance to GMO crops has been widespread for much of the past decade. Which actors on the landscape are opposing GMOs, how powerful are they, and will their opposition weaken if the current generation of GMO crops carrying improved agronomic traits is followed by a second generation of GMOs carrying improved nutrient traits?"

Journal Article - International Journal of Technology and Globalisation

Introduction: Global Actors, Markets and Rules Driving the Diffusion of Genetically Modified (GM) Crops in Developing Countries

| 2006

"This introductory essay explains how this new technology is being driven by the actors (multinational corporations), markets (large global markets) and rules (intellectual property) of globalisation."

teaser image

Journal Article - Environment: Science and Policy for Sustainable Development

Industrial Applications for Biotechnology: Opportunities for Developing Countries

| July / August 2002

Sustaining the bioeconomy will require the adoption of a governance regime for biotechnology that helps bring a large number of developing countries into the global trading system. Failure to do so will create a "genetic divide" among countries and likely will intensify public opposition to biotechnology that will be fueled by presumptions about possible market dislocation and apparent technological disparities among nations. 3 A global governance system will require improvements in market access, development of technological capabilities, access to technology, a favorable regulatory environment for biotechnology, and management of risks and benefits associated with its use.